Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the safety of the medicine eptacog alfa in women in India who experience severe heavy bleeding after giving birth, known as severe postpartum haemorrhage PPH. The study focuses on women aged 18 years or older who have given birth after 27 weeks of pregnancy and have PPH that does not respond to standard uterotonic treatments. The goal is to gather more knowledge about how safe eptacog alfa is when used for this purpose. Participants will receive a single intravenous bolus injection of eptacog alfa NovoSeven to help stop the bleeding. If the first dose does not stop the bleeding, an additional dose may be given. This study is a Phase IV interventional trial conducted with a single treatment group and will last about 30 to 35 days for each participant. During the study, participants will be monitored for any thromboembolic events from the start of treatment through 30 days after. Researchers will also track serious adverse events, allergic reactions, and any medication errors at baseline and throughout the study period. The study involves careful observation and safety monitoring to understand the effects of eptacog alfa in these women.
Actively Recruiting
Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.
Actively Recruiting
Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.
Actively Recruiting
Researchers are evaluating mavorixafor, a drug being studied for people aged 12 and older who have congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders. These conditions cause low neutrophil levels and lead to recurrent or serious infections. The study aims to show if mavorixafor can improve clinical outcomes and increase neutrophil counts, while also assessing its safety and tolerability. Participants will continue their current treatment during the study, which may include therapies like granulocyte-colony stimulating factor G-CSF, immunoglobulin replacement, antibiotics, or no active treatment. They will be randomly assigned to receive either mavorixafor or a placebo orally once daily for up to 52 weeks. The study uses a quadruple-blind design to compare these groups in parallel. During the trial, participants will have regular assessments to monitor infection rates and severity, neutrophil counts, antibiotic use, oral ulcers, and fatigue levels using questionnaires. An independent committee will review infections to ensure accuracy. Safety and treatment effects will be followed throughout the 52-week treatment period. The total participation may last until the study ends in late 2027.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are conducting a Phase 1 study to evaluate the safety and tolerability of SBO-154 in adults with advanced solid tumors who have either not responded to or cannot tolerate standard treatments. The study aims to find the highest dose of SBO-154 that patients can safely tolerate and then further assess its safety in specific advanced cancers. The study is divided into two parts. In Part 1, participants receive escalating doses of SBO-154 administered intravenously every three weeks to determine the maximum tolerated dose. In Part 2, the safety of the selected doses from Part 1 is further evaluated in patients with particular types of advanced solid tumors. Treatment continues with dosing every three weeks during the study period. Participants will be closely monitored through scheduled visits involving laboratory tests and assessments to track any dose-limiting toxicities and treatment-related adverse events up to 30 days after the last dose. Researchers will also evaluate tumor response using imaging every six weeks for up to 12 months and monitor the presence of anti-drug antibodies for up to one year. The overall study duration extends through 2030, with ongoing safety and response evaluations.
Actively Recruiting
Researchers are evaluating whether olomorasib combined with immunotherapy is more effective than standard immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study has two parts Part A focuses on participants with resected NSCLC treated with pembrolizumab, and Part B includes participants with unresectable NSCLC treated with durvalumab. This Phase 3 study aims to assess disease control and survival outcomes over several years. Participants will be randomly assigned to receive either olomorasib or a placebo, both given orally, combined with intravenous pembrolizumab or durvalumab depending on the study part. Treatment with the combination lasts for up to 1 year, followed by olomorasib or placebo alone for up to 3 years. The study involves parallel groups comparing these combinations in participants with either resected or unresectable disease. During the study, participants will have regular assessments including disease monitoring for progression or recurrence, quality of life questionnaires, and evaluations of lung cancer symptoms. Researchers will track outcomes such as disease-free survival in Part A and progression-free survival in Part B, along with overall survival and symptom changes. The total participation may last about 3 years, with ongoing follow-up to monitor safety and treatment effects.
Actively Recruiting
Researchers are studying oral squamous cell carcinoma, focusing on patients with advanced nodal disease N2-N3 who are operable and present biologically aggressive tumors. The study aims to evaluate whether adding induction chemotherapy before surgery improves 2-year disease-free survival compared to upfront surgery alone. This phase 3, open-label, multi-center randomized controlled trial addresses previous trial limitations by selecting a more homogenous patient group likely to benefit from chemotherapy. Secondary goals include assessing overall survival, treatment response, compliance, toxicity, postoperative complications, quality of life, and tumor biobanking for future research. The study compares two treatment approaches. The standard arm involves surgery wide local excision with comprehensive neck dissection followed by adjuvant radiotherapy with or without concurrent chemotherapy. The experimental arm adds two cycles of induction chemotherapy using TPF or TPX regimens before surgery and similar adjuvant treatment. Patients will receive standard care according to current guidelines, with surgery timed after assessing chemotherapy response. Participants aged 18 to 75 with confirmed operable oral squamous cell carcinoma and advanced nodal involvement will be followed for up to five years. Researchers will monitor disease-free survival at two years as the primary outcome, alongside overall survival, treatment completion, toxicity, quality of life assessments over multiple timepoints, and surgical morbidity. Tumor and blood samples will be collected for biobanking. Safety and quality of life will be tracked regularly, including early and late radiotherapy-related toxicities and financial impact questionnaires.